{
  "node_id": "us-21-cfr-part-320-bioavailability-bioequivalence",
  "title": "US 21 CFR Part 320: Bioavailability and Bioequivalence Requirements",
  "domain": "Pharmaceuticals & Life Sciences",
  "version": "1.0.0",
  "last_updated": "2026-05-31",
  "bluf": "US 21 CFR Part 320 sets the requirements for demonstrating bioavailability (BA) and bioequivalence (BE) for drug products submitted under NDA, ANDA, INDs, and supplements…",
  "paywall": {
    "status": "LOCKED",
    "unlock_cost_usd": "0.01",
    "skyfire_id": "41779894-ece2-4163-9761-b3b1b76e19b0"
  },
  "crosswalks": {
    "_available_keys": [
      "cfr_21_314",
      "ich_m9",
      "fda_bcs_guidance",
      "industry_mapping"
    ],
    "_note": "Full crosswalk values included in vault response"
  },
  "primary_citations_count": 5,
  "workflow_steps_count": 8,
  "schema_fields_count": 16,
  "citation_preview": [
    "Title 21 Code of Federal Regulations Bioavailability and Bioequivalence Requirements",
    "Title 21 Code of Federal Regulations Applications for FDA Approval to Market a New Drug"
  ]
}